Pathway cancels plans for genetic test after FDA scrutiny
This article was originally published in Clinica
Executive Summary
Pathway Genomics has halted plans to commercialise a genetic testing kit in stores of US retail pharmacy Walgreens after the FDA raised fears about the product’s regulatory status.